Carcinogenesis

IITRI has extensive experience evaluating the potential carcinogenicity of chemicals and physical agents using the two-year rodent bioassay. Such studies are required by the U.S. Food and Drug Administration (FDA) prior to approval of drugs proposed for long-term administration to humans. This experience enables us to provide our customers with investigative approaches to determine the potential carcinogenicity of a chemical or unique insight for new and innovative therapeutic treatments for carcinogenicity.

To provide a preliminary indication of the potential oncogenicity of novel agents, IITRI can also conduct more affordable and shorter-term studies in transgenic model systems. Our expertise in the development and use of site-specific animal cancer models is world-renowned. IITRI routinely conducts these studies in a wide array of animal models and often develops customized studies in response to customer requests.

Our efforts have resulted in the development and refinement of reproducible animal models with well-defined dose- and time-response parameters. Past experience and current initiatives include National Cancer Institute (NCI) programs in prostate, skin, urinary bladder, and head and neck, which have led to subsequent studies for the pharmaceutical companies providing drugs to the NCI.

When customers encounter new models or need new models developed, they look to IITRI for guidance and assistance.

Areas of Expertise Include:

• Carcinogenicity Bioassays
• Transgenic Tumor Models
• Tg:Ac
• P53
• H2ras
• Neonatal Mouse Model
• Organ Specific Models
• Brain
• Breast*
• Esophagus*
• Hematopoeitic System*
• Liver*
• Lung and Trachea*
• Oral Cavity*
• Pancreas
• Prostate*
• Skin*
• Urinary Bladder*

* These sites have in vivo models available for primary cancers.